The Global Transcatheter Cardiac Valve Replacement (THVR) Market, valued at USD 6.54 billion in 2023, is anticipated to grow significantly with a CAGR of 14.8% over the forecast period of 2024 to 2032. The market’s expansion is driven by an increasing demand for minimally invasive surgeries, the growing elderly population suffering from cardiovascular diseases, and advancements in TAVR technologies that improve patient outcomes and safety profiles. Transcatheter Aortic Valve Replacement (TAVR) is increasingly recognized as a less invasive alternative for patients with severe aortic stenosis or regurgitation who are deemed too high-risk for open-heart surgery.
The growing adoption of second-generation TAVR devices, which provide improved safety and lower the risks of paravalvular regurgitation and valve embolization, is expected to propel the market. Technological advancements, such as TAVR valves with smaller diameters, better sealing, and greater precision, are anticipated to further boost market growth. Moreover, ongoing clinical trials and innovations in the TAVR space present significant opportunities for market players to introduce advanced bioprosthetic valves.
North America is expected to dominate the market, driven by a well-established healthcare infrastructure, the presence of leading market players, and a growing elderly population. Europe is projected to follow, with increasing adoption of minimally invasive cardiovascular procedures and strong government support for advanced cardiac therapies. The Asia-Pacific region is anticipated to exhibit the fastest growth due to rising healthcare investments, increasing prevalence of cardiovascular diseases, and improvements in healthcare infrastructure.

Key Market Players include:
Abbott
Edwards Lifesciences Corporation
Medtronic
Boston Scientific Corporation
JenaValve Technology, Inc.
Meril Life Sciences
Sahajanand Medical Technologies Limited
MicroPort Scientific Corporation
Venus Medtech (Hangzhou) Inc.
Suzhou Jiecheng Medical Technology Co. Ltd.
Peijia Medical Limited
Blue Sail Medical Co., Ltd.

The detailed segments and sub-segments of the market are explained below:
By Product:

  • Self-Expandable Transcatheter Aortic Valves
  • Balloon-Expandable Transcatheter Aortic Valves
  • Mechanically Expanded Transcatheter Aortic Valves


By Indication:

  • Severe Aortic Valve Stenosis
  • Valve-in-Valve Procedures (Failed Bioprosthesis)
  • Aortic Regurgitation


By End User:

  • Hospitals
  • Independent Cardiac Catheterization Labs
  • Ambulatory Surgical Centres


By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa


Years considered for the study are as follows:

  • Historical year: 2022
  • Base year: 2023
  • Forecast period: 2024 to 2032


Key Takeaways:

  • Market estimates and forecasts for 10 years (2022-2032)
  • Detailed regional analysis with country-level breakdowns
  • Competitive landscape with information on major market players
  • Analysis of key strategies and recommendations for future market approaches
  • Emphasis on technological advancements and their impact on market dynamics